News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Despite a $17bn bid from Merck KGaA, it’s “business as usual” at Sigma-Aldrich which has signed a distribution agreement with reagent-based microbial growth systems firm BioSilta.
The WHO has accused biopharma firms of failing to invest in R&D to tackle Ebola due to the disease’s prevalence in poor African nations, as the death toll surpasses 4,000.
Biosimilars may be a global business, but the EMA is still setting the pace when it comes to regulations according to UK contractor, BioOutsource.